article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SNMMI Elects Jean-Luc C. Urbain, MD, PhD, FASNC, as President-Elect at 2024 Annual Meeting

Imaging Technology

Urbain, MD, PhD, FASNC, professor of Radiology/Nuclear Medicine and Medicine, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2024 Annual Meeting, held June 8-11 in Toronto. “As

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. He also helped lead the theranostics conference at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 midwinter meeting. However, few freestanding theranostics centers exist today. Hope added.